CymaBay Therapeutics Inc. (CBAY)
Stock Price:
$6.26 USD
0.53 (9.25%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $6.20 -0.06 (-0.96%) Aug 7, 7:59 PM
Key Info
| Market Cap |
431.20M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-92.82M |
| Shares Out |
68.88M |
| EPS (ttm) |
-1.35 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$6.26 |
| Previous Close |
$5.73 |
| Change ($) |
0.53 |
| Change (%) |
9.25% |
| Day's Open |
5.68 |
| Day's Range |
5.67 - 6.30 |
| Day's Volume |
5,422,641 |
| 52-Week Range |
1.21 - 6.56 |
More Stats
| Market Cap |
431.20M |
| Enterprise Value |
256.60M |
| Earnings Date (est) |
Aug 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
68.88M |
| Float |
55.55M |
| EPS (basic) |
-1.35 |
| EPS (diluted) |
-1.35 |
| FCF / Share |
-1.31 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
8.08M |
| Short Ratio |
5.09 |
| Short % of Float |
11.66% |
| Beta |
1.36 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.92 |
| Revenue |
n/a |
| Operating Income |
-97.83M |
| Net Income |
-92.82M |
| Free Cash Flow |
-90.36M |
| Net Cash |
174.60M |
| Net Cash / Share |
2.53 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-25.04% |
| ROE |
-42.91% |
| ROIC |
-55.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (10)
| Buy |
10 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$11.90*
(90.10% upside)
Low
7.00
Current: $6.26
High
20.00
Target: 11.90
*Average 12-month price target from 10 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | 10.00 | - | - | - | - | 3.05 | 15.15 |
| Revenue Growth | - | - | - | - | - | - | - | -79.86% | - |
| Gross Profit | - | - | 10.00 | - | - | - | - | 3.05 | 15.15 |
| Operating Income | -108 | -72.51 | -21.33 | -25.59 | -25.90 | -24.01 | -9.40 | -10.44 | -3.90 |
| Net Income | -103 | -72.55 | -27.56 | -26.67 | -15.53 | -31.92 | 244 | -23.90 | -4.50 |
| Shares Outstanding | 67.03 | 57.81 | 34.90 | 23.45 | 18.90 | 12.05 | 2.36 | 0.01 | 0.01 |
| Earnings Per Share | -1.53 | -1.26 | -0.79 | -1.14 | -0.83 | -2.65 | -3.54 | -4,128.71 | -2,963.11 |
| Operating Cash Flow | -97.91 | -54.94 | -19.63 | -23.35 | -23.32 | -21.11 | -8.46 | -11.29 | -17.93 |
| Capital Expenditures | -0.32 | -0.53 | -0.03 | -0.04 | - | -0.10 | 0.66 | - | -0.04 |
| Free Cash Flow | -98.23 | -55.47 | -19.66 | -23.40 | -23.32 | -21.22 | -7.80 | -11.29 | -17.96 |
| Cash & Equivalents | 191 | 179 | 97.21 | 16.99 | 41.48 | 34.80 | 31.24 | 7.73 | 19.03 |
| Total Debt | 1.74 | - | 6.10 | 8.80 | 9.31 | 4.51 | 4.45 | 13.74 | 13.76 |
| Net Cash / Debt | 189 | 179 | 91.11 | 8.20 | 32.17 | 30.29 | 26.80 | -6.01 | 5.27 |
| Assets | 206 | 187 | 104 | 19.36 | 43.08 | 37.47 | 32.50 | 8.12 | 19.79 |
| Liabilities | 19.38 | 16.33 | 19.30 | 15.42 | 14.96 | 23.62 | 13.90 | 17.99 | 18.55 |
| Book Value | 186 | 170 | 84.95 | 3.94 | 28.12 | 13.85 | 18.60 | -329 | -305 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
CymaBay Therapeutics Inc. |
| Country |
United States |
| Employees |
36 |
| CEO |
Sujal Shah |
Stock Information
| Ticker Symbol |
CBAY |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CBAY |
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.